Status:
RECRUITING
7 Tesla MRI Brain Imaging to Decipher Filgotinib's Mode of Analgesic Action in Rheumatoid Arthritis
Lead Sponsor:
NHS Greater Glasgow and Clyde
Collaborating Sponsors:
Galapagos NV
Conditions:
Rheumatoid Arthritis
Sickness Behavior
Eligibility:
All Genders
18-74 years
Brief Summary
This is an experimental medicine, single-centre, observational test-retest study to evaluate Filgotinib's mechanism of analgesic action in RA patients. The investigators hypothesize that Filgotinib's...
Detailed Description
The revolution in rheumatoid arthritis (RA) therapeutics has been transformative for many patient outcomes. Yet most patients continue to experience life disabling pain. Strikingly, even those who ach...
Eligibility Criteria
Inclusion
- Patients with moderate to severe active RA who have been prescribed filgotinib in line with the Summary of Product Characterisation and are:
- Adults ≥18 years \< 75 years.
- Right-handed (to reduce neuroimaging heterogeneity).
Exclusion
- Inability to provide written informed consent.
- Severe physical impairment (e.g. blindness, deafness, paraplegia).
- Pregnant or breast feeding.
- Severe claustrophobia precluding MRI.
- Contraindications to MRI.
- Major confounding neurological disease including MS, Stroke, Traumatic Brain Injury.
- Previous targeted synthetic (e.g. baricitinib, tofacitinib) DMARD exposure for RA.
Key Trial Info
Start Date :
August 22 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 31 2025
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05697159
Start Date
August 22 2023
End Date
October 31 2025
Last Update
January 14 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Neil Basu
Glasgow, United Kingdom